Boyoglu-Barnum, Seyhan
Ellis, Daniel
Gillespie, Rebecca A.
Hutchinson, Geoffrey B.
Park, Young-Jun http://orcid.org/0000-0003-2901-6949
Moin, Syed M.
Acton, Oliver J. http://orcid.org/0000-0003-3928-2300
Ravichandran, Rashmi
Murphy, Mike http://orcid.org/0000-0002-8438-2653
Pettie, Deleah http://orcid.org/0000-0002-5477-7195
Matheson, Nick
Carter, Lauren
Creanga, Adrian
Watson, Michael J.
Kephart, Sally http://orcid.org/0000-0002-2285-511X
Ataca, Sila
Vaile, John R.
Ueda, George http://orcid.org/0000-0002-9792-7149
Crank, Michelle C.
Stewart, Lance http://orcid.org/0000-0003-4264-5125
Lee, Kelly K.
Guttman, Miklos
Baker, David http://orcid.org/0000-0001-7896-6217
Mascola, John R.
Veesler, David http://orcid.org/0000-0002-6019-8675
Graham, Barney S. http://orcid.org/0000-0001-8112-0853
King, Neil P. http://orcid.org/0000-0002-2978-4692
Kanekiyo, Masaru http://orcid.org/0000-0001-5767-1532
Article History
Received: 29 May 2020
Accepted: 17 February 2021
First Online: 24 March 2021
Competing interests
: S.B.-B., D.E., R.A.G., G.U., B.S.G., N.P.K. and M.K. are listed as inventors on a patent application based on the studies presented in this paper. D.V. is a consultant for Vir Biotechnology Inc. The Veesler laboratory has received an unrelated sponsored research agreement from Vir Biotechnology Inc. N.P.K. is a co-founder, shareholder, and chair of the scientific advisory board of Icosavax, Inc. L.S. is a shareholder of Icosavax, Inc. The King laboratory has received an unrelated sponsored research agreement from Pfizer. D.B. is a co-founder and shareholder of Icosavax, Inc. All other authors declare no competing interests.